KalVista Pharmaceuticals, Inc. has provided an operational update and released financial results for the fiscal second quarter ended October 31, 2018. CEO Andrew Crockett says:
“We are still on track with our robust Phase 2 study for KVD900 as a potential acute therapy for patients with HAE. Our intention is to have an aggressive development plan for KVD900, and use this Phase 2 data set as a basis for discussions with regulators about a faster approval pathway.“
(Source: KalVista)
